Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD study

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 2, 2017, Pages 407-415

  Petit, Jean Michel ^a,b   Cercueil, Jean Pierre ^a   Loffroy, Romaric ^a   Denimal, Damien ^a,b   Bouillet, Benjamin ^a,b   Fourmont, Coralie ^a   Chevallier, Olivier ^a   Duvillard, Laurence ^a,b   Vergès, Bruno ^a,b,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FAT CONTENT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER FAT CONTENT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SCANNER; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TREATMENT DURATION; WEIGHT REDUCTION; ADIPOSE TISSUE; AGED; BODY WEIGHT LOSS; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS;

ADIPOSE TISSUE; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 85012093596     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2775     Document Type: Review

References (38)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-1231.
2. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6(9):e25269.
3. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice [published correction appears in Hepatology. 2006;44(2):515]. Hepatology. 2006;43(1):173-181.
4. Lee J, Hong S-W, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One. 2012;7(2):e31394.
5. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, EricksonMR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302(8):G762-G772.
6. Tong W, Ju L, Qiu M, Xie Q, Chen Y, Shen W, Sun W, Wang W, Tian J. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway. Hepatol Res. 2016; 46(9):933-943.
7. Kawaguchi T, ItouM, TaniguchiE, Sata M. Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and D-5-desaturase index in a murine model of non-alcoholic steatohepatitis. Int J Mol Med. 2014;34(3):782-787.
8. Armstrong MJ, Houlihan DD, Rowe IA, Clausen WH, Elbrønd B, Gough SC, Tomlinson JW, Newsome PN. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37(2):234-242.
9. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebocontrolled trials. Clin Ther. 2007;29(1):139-153.
10. Jendle J,NauckMA,MatthewsDR, FridA,HermansenK,DüringM, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagonlike peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163-1172.
11. Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med. 2013;52(10):1029-1034.
12. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series. Am J Gastroenterol. 2010;105(12):2707-2709.
13. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN; LEAN Trial Team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387(10019):679-690.
14. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7(12):e50117.
15. Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, Chartrand G, Olivié D, Julien AS, de Guise J, Soulez G, Chiasson JL. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial. Diabetes Care. 2015; 38(7):1339-1346.
16. Standards of medical care in diabetes-2016: Summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4-S5.
17. Guiu B, Petit J-M, Loffroy R, Ben Salem D, Aho S, Masson D, Hillon P, Krause D, Cercueil JP. Quantification of liver fat content: Comparison of triple-echo chemical shift gradient-echo imaging and in vivo protonMR spectroscopy. Radiology. 2009;250(1):95-102.
18. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40(6):1387-1395.
19. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462-E468.
20. Petit J-M, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Terriat B, Bouillet B, Brindisi MC, Loffroy R, Robin I, Hillon P, Cercueil JP, Verges B. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(12):E430-E436.
21. Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015; 45(3):269-278.
22. Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147-151.
23. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79-104.
24. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22): 2297-2307.
25. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011;54(6):1214-1223.
26. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres- Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-78.e5.
27. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242(4):610-617, discussion 618-620.
28. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603-608.
29. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4(5):639-644.
30. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):25-32.
31. Vergès B, Petit J-M, Bouillet B. Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis. Diabetes Metab. 2016;42(1):1-3.
32. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA. 2004;101(44):15597- 15602.
33. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia. 2015;58(5):886-899.
34. Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64(2):399-408.
35. Serrano A, Pavón FJ, Suarez J, Rivera P, Vida M, Bermúdez-Silva FJ, Alonso M, Martínez A, López-Ogalla J, Alonso-Gascón M, Santamaría G, Romero-Cuevas M, Pérez-Valero V, Baixeras E, Rodríguez de Fonseca F. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. Am J Physiol Endocrinol Metab. 2012;302(7):E817-E830.
36. Flechtner-Mors M, George SN, Oeztuerk S, Haenle MM, Koenig W, Imhof A, Boehm BO, Graeter T, Mason RA, Kratzer W, Akinli AS; EMIL-Study Group. Association of adiponectin with hepatic steatosis: A study of 1,349 subjects in a random population sample. BMC Res Notes. 2014;7:207.
37. Turer AT, Browning JD, Ayers CR, Das SR, Khera A, Vega GL, Grundy SM, Scherer PE. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab. 2012;97(6):E982-E986.
38. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91-100.